SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Analyst Ratings
NASDAQ:SNSE - US81728A2078 - Common Stock
8.32 USD
-0.49 (-5.6%)
ChartMill assigns a Buy % Consensus number of 87% to SNSE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.15. This target is 298.44% above the current price.
SNSE was analyzed by 9 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about SNSE.
In the previous month the buy percentage consensus was at a similar level.
SNSE was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-28 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-03 | Citigroup | Reiterate | Buy -> Buy |
| 2024-05-24 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-05-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-14 | Stephens & Co. | Initiate | Overweight |
| 2023-12-04 | HC Wainwright & Co. | Initiate | Buy |
| 2022-12-13 | Citigroup | Initiate | Buy |
| 2022-10-03 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-03-10 | Piper Sandler | Maintains | Overweight |
| 2021-07-01 | Berenberg | Downgrade | Buy -> Hold |
| 2021-06-29 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2021-03-01 | Oppenheimer | Initiate | Outperform |
| 2021-03-01 | Piper Sandler | Initiate | Overweight |